1. Home
  2. Disease & Disorders
  3. Ridgefield, CT
  4. Kindness Over Muscular Dystrophy

Kindness Over Muscular Dystrophy

Kindness Over Muscular Dystrophy is ranked among disease & disorders organizations in Ridgefield, CT, with an America's Best Score of 67 out of 100, based on its 2025 Form 990.

  • Ridgefield, CT
  • Tax-exempt since 2019
  • EIN: 84-2603015
kindnessovermd.org ProPublica Charity Navigator
Is this your organization? Claim it Tax filings by year Nominate
67OF 100 Ranked in Ridgefield Disease & Disorders How this score is calculated

Organization summary

Kindness Over Muscular Dystrophy is a 501(c)(3) organization, classified under Disease & Disorders (NTEE G12). Contributions are tax-deductible.

Po Box 871, Ridgefield, CT 06877-8871

In fiscal year 2025 it reported $524,850 in revenue and $552,436 in expenses, with contributions making up 95.0% of revenue.

Work here? Claim this profile to add your mission, programs and logo.

What it does

From its own Form 990, as filed with the IRS

Mission · 2025 Form 990

The mission of the organization is to provide charitable giving to support muscular dystrophy research as well as benevolent assistance and advocacy to those in need.

Largest programs · fiscal year 2025

  • Provided grants to support research initiatives focused on duchenne muscular dystrophy (dmd), specifically targeting critical studies in gene therapy, crispr technologies and antisense oligonucleotide (aon) exon- skipping therapies. Key projects included research on neutralizing antibodies to enable viral redosing of gene therapies, various other gene therapy inititatives, a specific exon 33 crisp… Read more

    Provided grants to support research initiatives focused on duchenne muscular dystrophy (dmd), specifically targeting critical studies in gene therapy, crispr technologies and antisense oligonucleotide (aon) exon- skipping therapies. Key projects included research on neutralizing antibodies to enable viral redosing of gene therapies, various other gene therapy inititatives, a specific exon 33 crispr research study, and development of exon 33-trageted aon exon-skipping therapies. General dmd reseacch efforts aimed at developing effective treatments and a cure for the disease were also supported.

    $442,423 spent · 86.2% of program spending
  • Provided benevolent grants to support families affected by duchenne muscular dystrophy. Assistance included funding for essential mobility and accessibilityy needs such as travel scooters, wheelchairs, and accessible vans, as well as other general financial aid to help alleviate the burdens associated with living with duchenne muscular dystrophy. $70,538 spent · 13.8% of program spending

Where each dollar went · fiscal year 2025

Of every dollar it spent, 93¢ went to programs, 1¢ to management and 6¢ to fundraising.

  • Programs $512,961
  • Management $6,474
  • Fundraising $33,001

In the organization's own words to the IRS, shown for context. None of this affects the America's Best Score, and a Form 990 describes programs without measuring their results.

America's Best Score

Free assessmentMethodology
Score67 / 100
DesignationRanked

Score breakdown

MeasureThis organizationPoints
Operating reserves6.4 mo; 6.4 mo in cash4.5 / 25
Financial balance (median margin)+3.4%14.7 / 20
Transparency4 full 990s, latest TY202520 / 20
Program growth+15.5% / yr15 / 15
Track record7 years2.8 / 10
Debt load1.7% of assets10 / 10
Total67 → 67
Spending on programs
Not scored; America's Best needs 65%+
93%Meets

Tax filings by year

Financial data extracted from the Form 990 the organization filed with the IRS for each fiscal year. Revenue lines can exceed 100% when other items, such as fundraising event costs, are netted against total revenue.

Revenue$524,850Fiscal year 20252022: $386,79820222023: $518,44720232024: $508,89420242025: $524,8502025
Expenses$552,436Fiscal year 20252022: $358,88320222023: $523,09820232024: $401,88920242025: $552,4362025
Total assets$299,928Fiscal year 20252022: $224,85620222023: $220,38920232024: $334,36520242025: $299,9282025
Total liabilities$5,050Fiscal year 20252022: $4,46720222023: $4,65020232024: $11,62120242025: $5,0502025
Fiscal year ending December 2025
Revenue$524,850
Expenses$552,436
Net income−$27,586
Net assets$294,878

Notable sources of revenue

Percent of total revenue
Contributions$498,368
Program services$0
Investment income$78
Other (net)$26,404

Assets / debt

Total assets$299,928
Total liabilities$5,050
Net assets$294,878

Compensation

Not in our extract for this year.

Fiscal year ending December 2024
Revenue$508,894
Expenses$401,889
Net income$107,005
Net assets$322,744

Notable sources of revenue

Percent of total revenue
Contributions$452,819
Program services$0
Investment income$54
Other (net)$56,021

Assets / debt

Total assets$334,365
Total liabilities$11,621
Net assets$322,744

Compensation

Not in our extract for this year.

Fiscal year ending December 2023
Revenue$518,447
Expenses$523,098
Net income−$4,651
Net assets$215,739

Notable sources of revenue

Percent of total revenue
Contributions$504,087
Program services$0
Investment income$80
Other (net)$14,280

Assets / debt

Total assets$220,389
Total liabilities$4,650
Net assets$215,739

Compensation

Officers and key employees$0
Share of expenses0.0%
Fiscal year ending December 2022
Revenue$386,798
Expenses$358,883
Net income$27,915
Net assets$220,389

Notable sources of revenue

Percent of total revenue
Contributions$196,645
Program services$0
Investment income$64
Other (net)$190,089

Assets / debt

Total assets$224,856
Total liabilities$4,467
Net assets$220,389

Compensation

Officers and key employees$0
Share of expenses0.0%

About this data

Figures come from IRS Form 990 filings, through the IRS Exempt Organizations Business Master File (2026-11-09) and e-filed returns. Form 990 data typically lags 12–24 months behind an organization's fiscal year. Found an error?